{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:30:04Z","timestamp":1793478604298,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.pnpbp.2026.111966","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:35:35Z","timestamp":1791318935000},"page":"111966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review"],"prefix":"10.1016","volume":"150","author":[{"given":"Chad","family":"Collyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia Han","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2026.111966_bb0005","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1021\/acschemneuro.5c00667","article-title":"Zalsupindole is a nondissociative, nonhallucinogenic neuroplastogen with therapeutic effects comparable to ketamine and psychedelics","volume":"16","author":"Agrawal","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0014-2999(93)90427-J","article-title":"Intrathecal 5-methoxy-N, N-dimethyltryptamine in mice modulates 5-HT1 and 5-HT3 receptors","volume":"249","author":"Alhaider","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.13249","article-title":"Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies","volume":"143","author":"Andersen","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0020","series-title":"AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update","author":"AtaiBeckley Inc","year":"2026"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0304-3940(80)90198-6","article-title":"Nociception is enhanced after low doses and reduced after high doses of the serotonin receptor agonist 5-methoxy-N,N-dimethyltryptamine","volume":"19","author":"Berge","year":"1980","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0030","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41386-025-02167-3","article-title":"Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and\/or anxiety: a randomized, double-blind, placebo-controlled study","volume":"50","author":"Bistue Mill\u00f3n","year":"2025","journal-title":"Neuropsychopharmacol"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111966_bb0035","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1177\/02698811261465005","article-title":"Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression","volume":"40","author":"Bolcont","year":"2026","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drugalcdep.2010.03.015","article-title":"Dimethyltryptamine (DMT): subjective effects and patterns of use among Australian recreational users","volume":"111","author":"Cakic","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","article-title":"Towards an understanding of psychedelic-induced neuroplasticity","volume":"48","author":"Calder","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0050","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1021\/acschemneuro.8b00134","article-title":"Effects of N,N-dimethyltryptamine on rat behaviors relevant to anxiety and depression","volume":"9","author":"Cameron","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0055","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1021\/acschemneuro.8b00692","article-title":"Chronic, intermittent microdoses of the psychedelic N,N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents","volume":"10","author":"Cameron","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0065","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","article-title":"Neuropharmacology of N,N-dimethyltryptamine","volume":"126","author":"Carbonaro","year":"2016","journal-title":"Brain Res. Bull. Neurobiol. Emerg. Psychoactive Drugs"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0070","article-title":"Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics","volume":"15","author":"Chaves","year":"2024","journal-title":"Front. Psychol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2026.0096","article-title":"GH001 vs placebo in patients with treatment-resistant depression: a randomized clinical trial","author":"Cuba\u0142a","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0080","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/0269881118769063","article-title":"The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption","volume":"32","author":"Davis","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/00952990.2018.1545024","article-title":"5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety","volume":"45","author":"Davis","year":"2019","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0090","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/02791072.2020.1847366","article-title":"Persistent tinnitus after inhaled N,N-dimethyltryptamine (DMT)","volume":"53","author":"Diab","year":"2021","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0095","doi-asserted-by":"crossref","DOI":"10.1007\/s11011-025-01650-6","article-title":"Immunomodulatory and behavioral effects of ayahuasca and N, N-dimethyltryptamine in a rat model of lipopolysaccharide-induced depression","volume":"40","author":"do Nascimento Sousa","year":"2025","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0269881120986422","article-title":"Hallucinogenic\/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: evidence and mechanisms of action","volume":"35","author":"Dos Santos","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0105","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00213-023-06517-1","article-title":"5-MeO-DMT: an atypical psychedelic with unique pharmacology, phenomenology & risk?","volume":"242","author":"Dourron","year":"2025","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0110","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","article-title":"Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder","volume":"47","author":"D\u2019Souza","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0115","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1111\/cts.13410","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of the psychedelic experience induced by N,N-dimethyltryptamine \u2013 Implications for dose considerations","volume":"15","author":"Eckern\u00e4s","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0120","author":"Eckern\u00e4s"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0125","author":"Eckern\u00e4s"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01255814","article-title":"Subsensitivity of serotonin and substance P receptors involved in nociception after repeated administration of a serotonin receptor agonist","volume":"77","author":"Eide","year":"1989","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0135","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41386-024-02041-8","article-title":"Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants","volume":"50","author":"Erne","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-026-03987-7","article-title":"Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants","volume":"16","author":"Erne","year":"2026","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0145","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-025-04154-z","article-title":"A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial","volume":"32","author":"Erritzoe","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.euroneuro.2023.12.006","article-title":"Safety and tolerability of inhaled N,N-dimethyltryptamine (BMND01 candidate): A phase I clinical trial","volume":"80","author":"Falchi-Carvalho","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0155","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1089\/psymed.2024.0002","article-title":"The antidepressant effects of vaporized N,N-dimethyltryptamine: an open-label pilot trial in treatment-resistant depression","volume":"3","author":"Falchi-Carvalho","year":"2025","journal-title":"Psychedelic Med. (New Rochelle)"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0160","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41386-025-02091-6","article-title":"Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression","volume":"50","author":"Falchi-Carvalho","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0165","series-title":"GH Research Reports First Quarter 2026 Financial Results and Provides Business Update","author":"GH Research PLC","year":"2026"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0170","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s13318-023-00822-y","article-title":"Pharmacokinetics of N,N-dimethyltryptamine in Humans","volume":"48","author":"Good","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0175","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1523\/JNEUROSCI.1121-22.2022","article-title":"Psychedelics and neural plasticity: therapeutic implications","volume":"42","author":"Grieco","year":"2022","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0180","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00213-025-06777-z","article-title":"The evolution of N, N-dimethyltryptamine: from metabolic pathways to brain connectivity","volume":"242","author":"Gupta","year":"2025","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0185","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-023-01666-5","article-title":"Therapeutic mechanisms of psychedelics and entactogens","volume":"49","author":"Heifets","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111966_bb0190","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/02698811251361453","article-title":"Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics","volume":"40","author":"Higgins","year":"2026","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0195","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019S risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0200","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","article-title":"Treatment resistance in psychiatry: state of the art and new directions","volume":"27","author":"Howes","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0205","article-title":"Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial","volume":"14","author":"James","year":"2023","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111966_bb0210","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.25m16284","article-title":"Inhaled mebufotenin (GH001) for adult patients with postpartum depression: a phase 2a open-label clinical trial","volume":"87","author":"Johnson","year":"2026","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0220","series-title":"Frontiers in Psychiatry: Artificial Intelligence, Precision Medicine, and Other Paradigm Shifts","first-page":"17","article-title":"Classification of psychiatric disorders","author":"Kim","year":"2019"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0225","author":"Koch"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0230","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/eat.23322","article-title":"Treatment interventions for severe and enduring eating disorders: systematic review","volume":"53","author":"Kotilahti","year":"2020","journal-title":"Int. J. Eat. Disord."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1477996","article-title":"Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials","volume":"15","author":"Kwa\u015bny","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0240","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1037\/tra0000384","article-title":"Residual symptoms following empirically supported treatment for PTSD","volume":"11","author":"Larsen","year":"2019","journal-title":"Psychol. Trauma Theory Res. Pract. Policy"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0245","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jad.2024.03.165","article-title":"Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: a systematic review","volume":"355","author":"Le","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0250","doi-asserted-by":"crossref","DOI":"10.1017\/S109285292510045X","article-title":"Biased agonism in psychopharmacology: an opportunity to improve efficacy and safety of treatments","volume":"30","author":"Le","year":"2025","journal-title":"CNS Spectr."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.70344","article-title":"The serotonin 2B (5-HT2B) receptor: a narrative review of preclinical and clinical evidence on the safety considerations and therapeutic potential for the treatment of depression","author":"Le","year":"2026","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0260","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41398-026-03852-7","article-title":"Single-dose DMT reverses anhedonia and cognitive deficits via restoration of neurogenesis in a stress-induced depression model","volume":"16","author":"Lima da Cruz","year":"2026","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0265","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0270","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/wps.20771","article-title":"The clinical characterization of the adult patient with depression aimed at personalization of management","volume":"19","author":"Maj","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0275","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0022-3565(25)21407-0","article-title":"Evidence for involvement of 5-hydroxytryptamine1 receptors in antidepressant-like drug effects on differential-reinforcement-of-low-rate 72-second behavior","volume":"250","author":"Marek","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0280","author":"Marsden"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0285","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jsat.2018.07.012","article-title":"Persistence\/recurrence of and remission from DSM-5 substance use disorders in the United States: substance-specific and substance-aggregated correlates","volume":"93","author":"McCabe","year":"2018","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0290","series-title":"Treatment Resistance in Psychiatry: Risk Factors, Biology, and Management","first-page":"151","article-title":"Treatment resistance in post-traumatic stress disorder","author":"McFarlane","year":"2019"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0295","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/14740338.2023.2253144","article-title":"Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents","volume":"22","author":"McIntyre","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0300","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/14740338.2023.2248883","article-title":"Serotonin 5-HT2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents","volume":"22","author":"McIntyre","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0305","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0310","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1176\/appi.ajp.20230902","article-title":"Psychedelics for the treatment of psychiatric disorders: interpreting and translating available evidence and guidance for future research","volume":"182","author":"McIntyre","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0315","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/ph18010130","article-title":"Uncovering psychedelics: from neural circuits to therapeutic applications","volume":"18","author":"Melani","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines14030506","article-title":"Ayahuasca and its main component N,N-dimethyltryptamine (DMT) for the treatment of mental disorders: mechanisms of action, clinical studies, and tools to explore the human mind","volume":"14","author":"Melani","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0330","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0335","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0340","author":"NIH"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0345","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1476-5381.1991.tb12392.x","article-title":"Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents","volume":"104","author":"Njung\u2019e","year":"1991","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0350","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41380-024-02655-w","article-title":"Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice","volume":"30","author":"Nogueira","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0360","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0365","article-title":"Psychosis in a military veteran in the context of hallucinogen use: a case report","volume":"17","author":"Parhami","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0370","series-title":"Management of Treatment-Resistant Major Psychiatric Disorders","author":"PhD","year":"2012"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.119680","article-title":"Anxiety-related platform in zebrafish (Danio rerio) larvae: an integrated analysis of behavioural and molecular assay in drug screening research","volume":"201","author":"Potoczna","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0380","article-title":"5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study","volume":"14","author":"Ragnhildstveit","year":"2023","journal-title":"Front. Psychol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0390","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1176\/appi.ajp.20230890","article-title":"Benefits and challenges of ultra-fast, short-acting psychedelics in the treatment of depression","volume":"182","author":"Ramaekers","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0395","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/jnc.15587","article-title":"The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)","volume":"162","author":"Reckweg","year":"2022","journal-title":"J. Neurochem."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0400","article-title":"A phase 1\/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression","volume":"14","author":"Reckweg","year":"2023","journal-title":"Front. Psychol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0405","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/dta.1685","article-title":"Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study","volume":"7","author":"Riba","year":"2015","journal-title":"Drug Test Anal."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0410","doi-asserted-by":"crossref","DOI":"10.1177\/02698811261420087","article-title":"A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression","author":"Roberts","year":"2026","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0415","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s40337-025-01328-5","article-title":"Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED\u2013FED survey","volume":"13","author":"Rodan","year":"2025","journal-title":"J. Eat. Disord."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0420","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/02698811241246857","article-title":"Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants","volume":"38","author":"Rucker","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0425","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1021\/acschemneuro.5c00707","article-title":"Zalsupindole: a non-hallucinogenic psychoplastogen advancing psychedelic-inspired therapeutics","volume":"17","author":"Salfiti","year":"2026","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0430","series-title":"Neurobiology of Psychiatric Disorders","author":"Schlaepfer","year":"2012"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0435","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40263-025-01250-z","article-title":"Intranasal 5-MeO-DMT concomitant with SSRI for treatment-resistant depression: a proof-of-concept trial","volume":"40","author":"Seynaeve","year":"2026","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0440","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0166-4328(96)00081-2","article-title":"Human psychopharmacology of N,N-dimethyltryptamine","volume":"73","author":"Strassman","year":"1995","journal-title":"Behav. Brain Res. Serotonin"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0445","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","article-title":"Dose-response study of N,N-dimethyltryptamine in humans: I. Neuroendocrine, autonomic, and cardiovascular effects","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0450","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","article-title":"Dose-response study of N,N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0455","article-title":"The evolution of the classification of psychiatric disorders","volume":"6","author":"Sur\u00eds","year":"2016","journal-title":"Behav. Sci. (Basel, Switzerland)"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0460","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13386","article-title":"The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: a first look at therapeutic mechanisms of action","volume":"29","author":"Tap","year":"2024","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0465","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1042\/CS20211106","article-title":"Severe psychiatric disorders and general medical comorbidities: inflammation-related mechanisms and therapeutic opportunities","volume":"136","author":"Teixeira","year":"2022","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0470","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1038\/s41598-024-53363-y","article-title":"Effects of DMT on mental health outcomes in healthy volunteers","volume":"14","author":"Timmermann","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0475","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s00213-019-05236-w","volume":"236","author":"Uthaug","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0480","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00213-019-05414-w","article-title":"Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment","volume":"237","author":"Uthaug","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0485","author":"van der Heijden"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0490","article-title":"Pharmacokinetics, pharmacodynamics and safety of N,N-dimethyltryptamine administered intravenously in healthy smoking and non-smoking volunteers","author":"van der Heijden","year":"2026","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0495","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.adf0435","article-title":"Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors","volume":"379","author":"Vargas","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0500","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41398-023-02477-4","article-title":"Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants","volume":"13","author":"Vogt","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0505","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.euroneuro.2025.06.002","article-title":"Safety, tolerability and subjective effects of vaporized N,N-dimethyltryptamine: a randomized double-blind clinical trial","volume":"97","author":"Wie\u00dfner","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0510","series-title":"International Review of Neurobiology","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/bs.irn.2025.04.009","article-title":"Serotonergic psychedelics for depression: a comprehensive overview","author":"Wingert","year":"2025"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0515","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/eat.20978","article-title":"Minimizing and treating chronicity in the eating disorders: a clinical overview","volume":"45","author":"Wonderlich","year":"2012","journal-title":"Int. J. Eat. Disord."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0520","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jad.2024.01.142","article-title":"A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): a systematic review","volume":"350","author":"Wong","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2026.111966_bb0525","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1055\/a-2794-6487","article-title":"Cardiac consequences associated with psychedelic use: a systematic review of lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and 5-hydroxytryptamine 2B-mediated valvular heart disease","volume":"59","author":"Xu","year":"2026","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2026.111966_bb0530","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00225","article-title":"The role of serotonin 5-HT2A receptors in memory and cognition","volume":"6","author":"Zhang","year":"2015","journal-title":"Front. Pharmacol."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626003647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626003647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:48:43Z","timestamp":1793476123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626003647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":102,"alternative-id":["S0278584626003647"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111966","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111966","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111966"}}